Chemistry:QMPSB
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H22N2O4S |
| Molar mass | 410.49 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
QMPSB is an arylsulfonamide-based synthetic cannabinoid that has been sold as a designer drug.[1]
QMPSB was first discovered by Nathalie Lambeng and colleagues in 2007. It acts as a full agonist of the CB1 receptor and CB2 receptor with Ki values of 3 nM and 4 nM, respectively.[2] Many related derivatives were subsequently produced, with the main focus of this work being to increase selectivity for the non-psychoactive CB2 receptor.[3][4][5][6] This work led on from an earlier series of sulfamoyl benzamide derivatives for which a patent was filed in 2004.[7]
The quinolin-8-yl ester motif of QMPSB led to the discovery of other designer cannabinoids such as PB-22 and BB-22.[8]
See also
References
- ↑ "Identification of the novel synthetic cannabimimetic 8-quinolinyl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in herbal incense". Forensic Science International 260: 40–53. March 2016. doi:10.1016/j.forsciint.2015.12.001. PMID 26795397.
- ↑ "Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies". Bioorganic & Medicinal Chemistry Letters 17 (1): 272–7. January 2007. doi:10.1016/j.bmcl.2006.09.049. PMID 17027269.
- ↑ "Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity". Bioorganic & Medicinal Chemistry Letters 18 (5): 1725–9. March 2008. doi:10.1016/j.bmcl.2008.01.042. PMID 18255291.
- ↑ "Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands". Bioorganic & Medicinal Chemistry Letters 18 (9): 2830–5. May 2008. doi:10.1016/j.bmcl.2008.04.006. PMID 18430570.
- ↑ "CB2 selective sulfamoyl benzamides: optimization of the amide functionality". Bioorganic & Medicinal Chemistry Letters 19 (2): 309–13. January 2009. doi:10.1016/j.bmcl.2008.11.091. PMID 19091565.
- ↑ "Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability". Bioorganic & Medicinal Chemistry Letters 20 (1): 387–91. January 2010. doi:10.1016/j.bmcl.2009.10.062. PMID 19919895.
- ↑ "Sulfamoyl benzamide derivatives and methods of their use" US patent application 7297796, published Nov 20, 2007, assigned to Adolor Corporation
- ↑ "Synthetic cannabinoid receptor agonists: analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233.". Drug Testing and Analysis 13 (1): 175–196. 2020. doi:10.1002/dta.2913. PMID 32880103.
 |  |
